Revenue by Product

3 Months Ended

Mar. 31, 2020

Segment Reporting [Abstract]

Revenue by Product

Revenue by Product 

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. 

The following table presents a summary of total revenues by these products: 

	Three Months Ended March 31,
Revenues by Product:	2020			2019
Bloxiverz	$	1,401		$	2,568
Vazculep	5,514			9,473
Akovaz	5,349			3,792
Other	(21		)	604
Total product sales	$	12,243		$	16,437